New drug cocktail aims to crush prostate tumors before knife
NCT ID NCT00329043
First seen Nov 10, 2025 · Last updated Jun 11, 2026 · Updated 34 times
Summary
This study tests whether adding the drug sunitinib to standard hormone therapy can better shrink or control high-risk prostate cancer before the prostate is removed. About 64 men with aggressive, localized prostate cancer will receive the combination treatment for a few months, then undergo surgery. The main goal is to see if the cancer completely disappears in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.